Navigation Links
MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference
Date:8/3/2015

MARIETTA, Ga., Aug. 3, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at the 35th Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Wednesday, August 12, 2015, at 5:00 p.m. EDT, at the InterContinental Boston.  A webcast of this presentation will be available on the Company's website, www.mimedx.com.

About MiMedx

MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  Our biomaterial platform technologies are AmnioFix®, EpiFix® and CollaFix™. AmnioFix® and EpiFix® are our tissue technologies processed from human amniotic membrane derived from donated placentas.  Through our donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx is the leading supplier of amniotic tissue, having supplied over 450,000 allografts to date for application in the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. CollaFix™, our next technology platform we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.  CollaFix™ is the only biological, biodegradable, biomimetic technology that matches human tendon in strength and stiffness.


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
2. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
3. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
4. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
5. MiMedx Announces Record First Quarter 2013 Results
6. MiMedx Secures a $3.0 Million Revolving Line of Credit with Bank of America
7. MiMedx to Present at Jefferies 2013 Global Healthcare Conference
8. MiMedx to Ring NASDAQ Stock Market Opening Bell
9. MiMedx To Exceed High End Of Second Quarter Guidance
10. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
11. MiMedx Announces Record Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):